Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California. Show more
Location: 680 East Colorado Boulevard, Pasadena, CA, 91101, United States | Website: https://lixte.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
2.495M
52 Wk Range
$0.64 - $3.00
Previous Close
$0.90
Open
$1.03
Volume
12,688,253
Day Range
$0.90 - $1.54
Enterprise Value
4.544M
Cash
1.385M
Avg Qtr Burn
-735.9K
Insider Ownership
18.43%
Institutional Own.
15.84%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LB-100 + dostarlimab-gxly Details Cancer, Ovarian clear cell carcinoma | Phase 1/2 Data readout | |
LB-100 +atezolizumab Details Cancer, Metastatic colorectal cancer | Phase 1 Data readout |